Single Dose Study of MK-6482 in Healthy Japanese Female Participants

JRCT ID: jRCT2031220024

Registered date:16/04/2022

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Renal Cell Carcinoma
• Date of first enrollment: 21/04/2022
• Target sample size: 24
• Study type: Interventional

Intervention(s)

- Palens A and C
Single dose of MK-6482 80 mg will be administerd.
- Palens B and D
Single dose of MK-6482 120 mg will be administerd.

Outcome(s)

• Primary Outcome: pharmacokinetics (Cmax, Tmax, AUC0-last, AUC0-inf, CL/F, Vz/F and t1/2)
• Secondary Outcome: Safety (Adverse events)

Key inclusion & exclusion criteria

• Age minimum: >= 45age old
• Age maximum: <= 64age old
• Gender: Female
• Include criteria: Healthy female participants of nonchildbearing potential between the ages of 45 and 64 years
• Exclude criteria: Has a history of clinically significant abnormalities or diseases

Related Information

• Primary Sponsor: Tanaka Yoshiyuki
• Secondary ID(s): Nil known